These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 32616873

  • 1. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
    Wu RC, Chen SJ, Chen HC, Tan KT, Jung SM, Lin CY, Chao AS, Huang KG, Chou HH, Chang TC, Chao A, Lai CH.
    Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
    [Abstract] [Full Text] [Related]

  • 2. Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.
    Sasamori H, Nakayama K, Razia S, Yamashita H, Ishibashi T, Ishikawa M, Sato S, Nakayama S, Otsuki Y, Fujiwaki R, Ishikawa N, Kyo S.
    Curr Oncol; 2022 May 18; 29(5):3658-3667. PubMed ID: 35621684
    [Abstract] [Full Text] [Related]

  • 3. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF, McIntyre JB, Taylor J, Lee S, Ogilvie T, Sienko A, Morris D, Duggan MA, McCluggage WG, Köbel M.
    Am J Surg Pathol; 2017 May 18; 41(5):685-695. PubMed ID: 28125452
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
    Lee YJ, Lee MY, Ruan A, Chen CK, Liu HP, Wang CJ, Chao WR, Han CP.
    Oncotarget; 2016 Dec 13; 7(50):82097-82103. PubMed ID: 27888800
    [Abstract] [Full Text] [Related]

  • 6. Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.
    Kim YM, Lee SW, Chun SM, Kim DY, Kim JH, Kim KR, Kim YT, Nam JH, van Hummelen P, MacConaill LE, Hahn WC, Jang SJ.
    PLoS One; 2014 Dec 13; 9(6):e99451. PubMed ID: 24936796
    [Abstract] [Full Text] [Related]

  • 7. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
    Tafe LJ, Muller KE, Ananda G, Mitchell T, Spotlow V, Patterson SE, Tsongalis GJ, Mockus SM.
    Am J Pathol; 2016 Mar 13; 186(3):671-7. PubMed ID: 26797085
    [Abstract] [Full Text] [Related]

  • 8. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF, Tsai EM, Chen CC, Wu CC, Er TK.
    Clin Chim Acta; 2019 Jul 13; 494():1-7. PubMed ID: 30851247
    [Abstract] [Full Text] [Related]

  • 9. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
    Nagasawa S, Ikeda K, Horie-Inoue K, Sato S, Takeda S, Hasegawa K, Inoue S.
    Endocr J; 2020 Feb 28; 67(2):219-229. PubMed ID: 31748433
    [Abstract] [Full Text] [Related]

  • 10. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
    Mirkovic J, McFarland M, Garcia E, Sholl LM, Lindeman N, MacConaill L, Dong F, Hirsch M, Nucci MR, Quick CM, Crum CP, McCluggage WG, Howitt BE.
    Am J Surg Pathol; 2018 Feb 28; 42(2):227-233. PubMed ID: 28984674
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.
    Basturk O, Tan M, Bhanot U, Allen P, Adsay V, Scott SN, Shah R, Berger MF, Askan G, Dikoglu E, Jobanputra V, Wrzeszczynski KO, Sigel C, Iacobuzio-Donahue C, Klimstra DS.
    Mod Pathol; 2016 Sep 28; 29(9):1058-69. PubMed ID: 27282351
    [Abstract] [Full Text] [Related]

  • 13. Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a Challenging Entity.
    Skálová A, Baněčková M, Laco J, Di Palma S, Agaimy A, Ptáková N, Costes-Martineau V, Petersson BF, van den Hout MFCM, de Rezende G, Klubíčková N, Koblížek M, Koshyk O, Vaneček T, Leivo I.
    Am J Surg Pathol; 2022 Feb 01; 46(2):268-280. PubMed ID: 34510113
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK.
    J Pathol; 2013 Dec 01; 231(4):449-56. PubMed ID: 24549645
    [Abstract] [Full Text] [Related]

  • 17. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
    Shibuya Y, Tokunaga H, Saito S, Shimokawa K, Katsuoka F, Bin L, Kojima K, Nagasaki M, Yamamoto M, Yaegashi N, Yasuda J.
    Genes Chromosomes Cancer; 2018 Feb 01; 57(2):51-60. PubMed ID: 29044863
    [Abstract] [Full Text] [Related]

  • 18. PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis.
    Yun BS, Won S, Kim JH, Lee N, Kim M, Kim MK, Kim ML, Jung YW, Kim JY, Seong SJ, Shin E.
    J Ovarian Res; 2022 Apr 06; 15(1):41. PubMed ID: 35387670
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.
    BMC Cancer; 2015 May 19; 15():415. PubMed ID: 25986173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.